Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Reply from Robert Farrell Jan 5th

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Jan 09, 2021 11:08am

234 Views

Post# 32261116

RE:RE:Reply from Robert Farrell Jan 5th

Thank you for posting this, Seems Stockhouse is the only place we can get the truth, Between Kalyterian and The Facebook Kaly Group making stuff up for the last 6.5 Months of this Halt, Nice to see someone post something Legit.

TheQQMon wrote:
Hello [TheQQMon],

On Thursday last week, we received another set of comments and questions from the BCSC, which we have responded to.

The BCSC is also requiring that we issue a press release that will include a fulsome discussion of the risks inherent with developing R-107 for Covid-19, such as the need to raise funds for clinical studies, and the risk that clinical studies may not be successful, etc.

We submitted the draft press release to the BCSC along with our responses to their comments and questions.

I expect to receive comments on the draft press release by tomorrow. We will make whatever changes they request, and then issue the press release.

We may be nearing the end of this process with the BCSC.

Bob

Robert E. Farrell

President and CEO

Kalytera Therapeutics, Inc.

Mobile Phone: 415-218-3900

Email: bfarrell@kalytera.co

www.kalytera.co